Mitoxantrone


Mitoxantrone (DHAD) has been synthesized by systematic substitution on the basic anthraquinone nucleus. It is used in the treatment of refractory cancers (advanced breast cancer).
 
Incidence
Less than 1%.
 
Clinical manifestations

General: anaphylactic shock.
 
Cutaneous: rashes (vesicular and erythematous), facial edema.
 
Diagnostic methods
Skin biopsy: leukocytoclastic vasculitis in a case of erythematous vesicular rash.
 
Mechanisms
Unknown.
 
Management
Avoidance.

References

  1. Taylor W.B, Cantwell B.M, Roberts J.T, Harris A.L, "Allergic reactions to mitoxantrone", Lancet, 1986; 1 (8495): 1439
  2. Anderson K.C, Cohen G.I, Garnick M.B, "Phase II trial of mitoxantrone", Cancer. Treat. Rep, 1982; 66 (11): 1929-31

As in all diagnostic testing, the diagnosis is made by the physican based on both test results and the patient history.